ATE526018T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents
Verbindungen zur behandlung von stoffwechselstörungenInfo
- Publication number
- ATE526018T1 ATE526018T1 AT04750363T AT04750363T ATE526018T1 AT E526018 T1 ATE526018 T1 AT E526018T1 AT 04750363 T AT04750363 T AT 04750363T AT 04750363 T AT04750363 T AT 04750363T AT E526018 T1 ATE526018 T1 AT E526018T1
- Authority
- AT
- Austria
- Prior art keywords
- carbon atoms
- ring
- alkyl
- hydrogen
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 perfluoromethoxy Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46666303P | 2003-04-30 | 2003-04-30 | |
| PCT/US2004/012141 WO2004098496A2 (en) | 2003-04-30 | 2004-04-20 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526018T1 true ATE526018T1 (de) | 2011-10-15 |
Family
ID=33434973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04750363T ATE526018T1 (de) | 2003-04-30 | 2004-04-20 | Verbindungen zur behandlung von stoffwechselstörungen |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7442796B2 (de) |
| EP (1) | EP1617835B1 (de) |
| JP (1) | JP4837557B2 (de) |
| KR (1) | KR101192272B1 (de) |
| CN (1) | CN100348186C (de) |
| AT (1) | ATE526018T1 (de) |
| AU (1) | AU2004237602B2 (de) |
| CA (1) | CA2522738C (de) |
| IL (1) | IL171638A (de) |
| MX (1) | MXPA05011592A (de) |
| NZ (1) | NZ543789A (de) |
| WO (1) | WO2004098496A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230352B1 (hu) * | 2001-06-12 | 2016-02-29 | Wellstat Therapeutics Corporation | Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények |
| US7615575B2 (en) * | 2003-02-13 | 2009-11-10 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2353601T3 (es) * | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| JP4697973B2 (ja) * | 2003-04-22 | 2011-06-08 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| ATE526018T1 (de) * | 2003-04-30 | 2011-10-15 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| WO2005018628A1 (en) * | 2003-08-20 | 2005-03-03 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8022249B2 (en) * | 2005-04-01 | 2011-09-20 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| CN101374415A (zh) * | 2006-01-25 | 2009-02-25 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CA2637373A1 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2007087505A2 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| NZ570334A (en) * | 2006-02-02 | 2011-07-29 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
| EP1983972A4 (de) * | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| EP1988772B1 (de) * | 2006-02-28 | 2011-10-26 | Wellstat Therapeutics Corporation | Verbindungen zur behandlung von stoffwechselstörungen |
| JP2009532372A (ja) * | 2006-03-31 | 2009-09-10 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の併用治療 |
| NZ572681A (en) * | 2006-05-18 | 2012-01-12 | Wellstat Therapeutics Corp | Aromatic acetal carboxylic acid derivatives for the treatment of metabolic disorders |
| JP5252585B2 (ja) * | 2006-06-09 | 2013-07-31 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| AU2007285827A1 (en) * | 2006-08-17 | 2008-02-21 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
| JP5496913B2 (ja) * | 2008-01-15 | 2014-05-21 | ウェルスタット セラピューティクス コーポレイション | 代謝異常の治療のための化合物 |
| RU2501555C2 (ru) | 2008-03-13 | 2013-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения и способ снижения мочевой кислоты |
| US8664433B2 (en) * | 2008-05-05 | 2014-03-04 | Wellstat Therapeutics Corporation | Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid |
| EP2365746B1 (de) | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthese von (phenylalkyloxy)phenyloxobutansäuren |
| US8337835B2 (en) * | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE949521C (de) * | 1955-01-09 | 1956-09-20 | Merck Ag E | Lichtschutzmittel |
| FI66005C (fi) * | 1975-02-04 | 1984-08-10 | Fujisawa Pharmaceutical Co | Foerfarande foer framstaellning av antibakteriellt verkande 7-alfa alfa-disubstituerad-acetamido)-3-substituerad-3-cefe m--karboxylsyras syn-isomer |
| AU543804B2 (en) * | 1980-10-31 | 1985-05-02 | Takeda Chemical Industries Ltd. | Amides having bicyclic substituents on nitrogen |
| US4474809A (en) | 1983-01-20 | 1984-10-02 | American Cyanamid Company | Arylglyoxals |
| JPS6261587A (ja) * | 1985-09-12 | 1987-03-18 | Ajinomoto Co Inc | 光学活性（ｒ）−ヒドロキシマンデル酸エステル中間体の製造法 |
| DE3806874A1 (de) * | 1988-03-03 | 1989-09-14 | Basf Ag | Substituierte hydrazone und diese enthaltende fungizide |
| JP2533651B2 (ja) * | 1988-09-13 | 1996-09-11 | 財団法人相模中央化学研究所 | ２―オキソ―３―芳香族カルボン酸誘導体の製造方法 |
| ATE136018T1 (de) * | 1991-05-09 | 1996-04-15 | Hoffmann La Roche | Substituierte carbonsäurederivate |
| US5589492A (en) * | 1992-04-10 | 1996-12-31 | Smithkline Beecham Plc | Heterocyclic compounds and their use in the treatment of Type-II diabetes |
| IL111613A0 (en) * | 1993-11-12 | 1995-01-24 | Rhone Poulenc Rorer Ltd | Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them |
| US5453443A (en) * | 1994-07-20 | 1995-09-26 | Merck Frosst Canada, Inc. | Bis(aryloxy)alkanes as inhibitors of phospholipase A2 enzymes |
| US5665387A (en) * | 1994-09-01 | 1997-09-09 | K.U. Leuven Research & Development | Methods and compositions for primary and secondary prevention of autoimmune diabetes |
| WO1999011255A1 (en) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| WO2001019777A1 (en) * | 1999-09-16 | 2001-03-22 | Takeda Chemical Industries, Ltd. | α-KETO ESTERS AND PROCESSES FOR THE PREPARATION THEREOF |
| GB9927056D0 (en) * | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| HU230352B1 (hu) * | 2001-06-12 | 2016-02-29 | Wellstat Therapeutics Corporation | Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények |
| JP2006507303A (ja) * | 2002-11-01 | 2006-03-02 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| US7615575B2 (en) * | 2003-02-13 | 2009-11-10 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2353601T3 (es) * | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| JP4697973B2 (ja) * | 2003-04-22 | 2011-06-08 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| ATE526018T1 (de) * | 2003-04-30 | 2011-10-15 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| WO2005018628A1 (en) | 2003-08-20 | 2005-03-03 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CN101374415A (zh) | 2006-01-25 | 2009-02-25 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CA2637373A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2007087505A2 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2004
- 2004-04-20 AT AT04750363T patent/ATE526018T1/de not_active IP Right Cessation
- 2004-04-20 US US10/554,586 patent/US7442796B2/en not_active Expired - Lifetime
- 2004-04-20 EP EP04750363A patent/EP1617835B1/de not_active Expired - Lifetime
- 2004-04-20 CN CNB2004800115527A patent/CN100348186C/zh not_active Expired - Fee Related
- 2004-04-20 NZ NZ543789A patent/NZ543789A/en not_active IP Right Cessation
- 2004-04-20 WO PCT/US2004/012141 patent/WO2004098496A2/en not_active Ceased
- 2004-04-20 MX MXPA05011592A patent/MXPA05011592A/es active IP Right Grant
- 2004-04-20 JP JP2006513150A patent/JP4837557B2/ja not_active Expired - Fee Related
- 2004-04-20 KR KR1020057020647A patent/KR101192272B1/ko not_active Expired - Fee Related
- 2004-04-20 CA CA2522738A patent/CA2522738C/en not_active Expired - Fee Related
- 2004-04-20 AU AU2004237602A patent/AU2004237602B2/en not_active Ceased
-
2005
- 2005-10-27 IL IL171638A patent/IL171638A/en not_active IP Right Cessation
-
2008
- 2008-09-11 US US12/208,877 patent/US7749990B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004098496A2 (en) | 2004-11-18 |
| IL171638A (en) | 2011-06-30 |
| CA2522738A1 (en) | 2004-11-18 |
| EP1617835B1 (de) | 2011-09-28 |
| US20090005451A1 (en) | 2009-01-01 |
| US7442796B2 (en) | 2008-10-28 |
| NZ543789A (en) | 2008-03-28 |
| JP4837557B2 (ja) | 2011-12-14 |
| US20070173544A1 (en) | 2007-07-26 |
| EP1617835A4 (de) | 2009-11-18 |
| AU2004237602B2 (en) | 2009-05-28 |
| HK1083460A1 (en) | 2006-07-07 |
| KR101192272B1 (ko) | 2012-10-17 |
| MXPA05011592A (es) | 2005-12-15 |
| JP2006525331A (ja) | 2006-11-09 |
| CA2522738C (en) | 2011-11-08 |
| EP1617835A2 (de) | 2006-01-25 |
| KR20060006075A (ko) | 2006-01-18 |
| AU2004237602A1 (en) | 2004-11-18 |
| WO2004098496A3 (en) | 2005-03-31 |
| CN1780614A (zh) | 2006-05-31 |
| US7749990B2 (en) | 2010-07-06 |
| CN100348186C (zh) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007087505A3 (en) | Compounds for the treatment of metabolic disorders | |
| UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
| WO2007137008A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007095462A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| NO20003399L (no) | <Alfa>-amionoamidderivater som er nyttige som smertestillende midler | |
| TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| UA88772C2 (ru) | Соединения для лечения расстройств метаболизма | |
| ATE540675T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007087504A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007092729A3 (en) | Compounds for the treatment of metabolic disorders | |
| MXPA06000651A (es) | Uso de derivados de indazol para el tratamiento de dolor neuropatico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |